Aslan Bullish On Once-Monthly Dosing For Eblasakimab In Atopic Dermatitis

 
• By Jessica Merrill
  
raise the bar
Aslan says it raised the efficacy bar in AD; investors aren't as sure • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D